Compare NXL & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXL | NAII |
|---|---|---|
| Founded | 2010 | 1980 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 16.9M |
| IPO Year | N/A | 1995 |
| Metric | NXL | NAII |
|---|---|---|
| Price | $0.40 | $2.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 208.5K | 18.6K |
| Earning Date | 03-13-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $132,437,000.00 |
| Revenue This Year | $38.28 | N/A |
| Revenue Next Year | $185.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.60 |
| 52 Week Low | $0.37 | $2.33 |
| 52 Week High | $2.57 | $4.96 |
| Indicator | NXL | NAII |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 36.92 |
| Support Level | $0.37 | $2.60 |
| Resistance Level | $0.62 | $2.89 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 8.79 | 16.33 |
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products, to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segments. The company derives the majority of revenue from Private-Label Contract Manufacturing, which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.